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ABSTRACT
Objectives Tropomyosin receptor kinase A (TrkA)
mediates nociceptor sensitisation by nerve growth factor
(NGF), but it is unknown whether selective TrkA
inhibition will be an effective strategy for treating
osteoarthritis (OA) pain. We determined the effects of a
TrkA inhibitor (AR786) on pain behaviour, synovitis and
joint pathology in two rat OA models.
Methods Knee OA was induced in rats by intra-
articular monosodium-iodoacetate (MIA) injection or
meniscal transection (MNX) and compared with saline-
injected or sham-operated controls. Pain behaviour was
assessed as weight-bearing asymmetry and paw
withdrawal threshold to punctate stimulation. Oral doses
(30 mg/kg) of AR786 or vehicle were administered twice
daily in either preventive (day −1 to –27) or treatment
(day 14–28) protocols. Effect maintenance was
evaluated for 2 weeks after treatment discontinuation.
Alterations in knee structure (cartilage, subchondral bone
and synovium) were examined by macroscopic
visualisation of articular surfaces and histopathology.
Results Preventive AR786 treatment inhibited pain
behaviour development and therapeutic treatment
attenuated established pain behaviour. Weight-bearing
asymmetry increased 1 week after treatment
discontinuation, but remained less than in vehicle-treated
arthritic rats, whereas paw withdrawal thresholds
returned to levels of untreated rats within 5 days of
treatment discontinuation. AR786 treatment reduced
MIA-induced synovitis and did not signiﬁcantly affect
osteochondral pathology in either model.
Conclusions Blocking NGF activity by inhibiting TrkA
reduced pain behaviour in two rat models of OA.
Analgesia was observed both using preventive and
treatment protocols, and was sustained after treatment
discontinuation. Selective inhibitors of TrkA therefore
hold potential for OA pain relief.
INTRODUCTION
Osteoarthritis (OA) is a common cause of pain and
disability and pain is the most common reason suf-
ferers seek medical help. Despite increased under-
standing of OA pathogenesis, the mechanisms by
which OA is painful remain incompletely under-
stood. Pathological characteristics that have been
associated with OA pain include chondropathy,
synovitis and subchondral bone marrow lesions.1–3
Concurrent with the development of OA, sensitisa-
tion of nociceptive pathways augments arthritis
pain.4 Arthritis pain therefore depends on a
combination of pathology within the joint and per-
ipheral and central neuronal sensitisation.
Nerve growth factor (NGF) plays a key role in
acute and chronic pain states, especially those asso-
ciated with inﬂammation.5–7 Sequestering NGF
reduces pain in experimental models,8 9 and NGF
blockade reduces OA pain and improves function
in randomised clinical trials10–12 more effectively
than that observed with non-steroidal anti-
inﬂammatory drugs or opiates.13 These data
support targeting of NGF pathways for the relief of
OA pain. Clinical trials of NGF blockers, although
demonstrating analgesic efﬁcacy, also revealed evi-
dence of an increased risk of rapidly progressive
OA (RPOA), leading to joint replacement surgery
in some treated participants.14
Inhibiting the high-afﬁnity NGF receptor TrkA
might prevent NGF-mediated sensitisation.
Speciﬁcity for TrkA might be important in order to
avoid possible adverse events from blocking other
Trk receptors. For example, disruption of the brain-
derived neurotrophic factor(BDNF)-TrkB pathway
can lead to hyperphagia and obesity in mice.15
Small-molecule, orally active inhibitors might also
be more acceptable and cost effective than mono-
clonal antibodies,16 17 but selectivity for TrkA
against related tyrosine kinase receptors has proved
difﬁcult to achieve. AR786 is a novel orally active
inhibitor of TrkA kinase activity. We hypothesise
that AR786 might reproduce the analgesic beneﬁts
of anti-NGF antibodies.
Reducing sensitisation by NGF signalling block-
ade is not anticipated to block normal, protective,
nociceptive signalling,18 unlike traditional analge-
sics such as opiates. Withdrawal of traditional
analgesics that block nociceptive transmission leads
to a rapid increase in pain. Peripheral sensitisation
is mediated, in part, by altered gene expression,19
and inhibitors of sensitisation might be expected to
have a slower onset of action but more sustained
effect than do directly acting analgesics.20
We used AR786 to explore the contribution of
the NGF-TrkA pathway to pain behaviour, synovitis
and joint pathology in the monosodium-iodoacetate
(MIA) and meniscal transection (MNX) rat models
of OA. We also investigated the duration of sus-
tained analgesia following withdrawal of treatment.
MATERIALS AND METHODS
Studies were carried out on male Sprague–Dawley
rats (Charles River, Kent, UK), n=100, in accord-
ance with UK Home Ofﬁce regulations and
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followed the guidelines of the International Association for the
Study of Pain.
OA induction
Rats weighing 200–250 g were anaesthetised brieﬂy with isoﬂur-
ane (2% in O2) and received a single intra-articular injection of
MIA (1 mg/50 mL; Sigma-Aldrich, UK; n=2021) in sterile 0.9%
saline or underwent transection of the medial meniscus (n=50).22
Non-osteoarthritic (saline; n=10 or SHAM; n=20) rats were used
as controls. All outcome measurements were carried out by an
experimenter blinded to randomised treatments.
Behavioural measurements of OA pain
Pain behaviour was measured as hindlimb weight-bearing asym-
metry and as reduced paw withdrawal thresholds to punctate
stimulation of the hind paw.21 Baseline measurements were
obtained immediately prior to intra-articular injection or
surgery (day 0) and every 2–4 days from day 3 onwards to day
21 for the therapeutic study or day 28 for the preventive study.
Weight-bearing asymmetry was assessed as percent difference in
weight distribution between hindlimbs.23
TrkA inhibitor (AR786) administration
AR786 (Array Biopharma, Boulder, Colorado, USA) was admi-
nistered in a therapeutic or preventive protocol based on previ-
ous data.17 24
To evaluate the effects of therapeutic treatment of AR786 in
the MIA and MNX models of OA, AR786 (30 mg/kg, orally
twice daily) or 5% Gelucire 50/13 vehicle (Gattefosse, Cedex,
France) was administered twice daily for 7 days from 2 weeks
after OA induction (after OA was established). Rats were strati-
ﬁed into groups of n=10 at day 10 by a researcher not other-
wise involved in the study. This was to avoid clinically
important differences in weight-bearing asymmetry between
arthritic groups that might otherwise occur by chance during
randomisation prior to treatment. Rats received either AR786
(MIA or MNX+drug) or vehicle (MIA or MNX+vehicle; saline
or SHAM+vehicle).
To evaluate the effects of AR786 preventive treatment and
treatment withdrawal in the MNX model, AR786 (30 mg/kg,
orally twice daily) or vehicle (5% Gelucire 50/13) was adminis-
tered 1 h prior to and 8 h following OA induction, and there-
after until the end of the study (day 28 after OA induction).
AR786 treatment was discontinued and replaced with vehicle in
some rats 2 weeks after continuous treatment. Rats were strati-
ﬁed into treatment groups each comprising 10 animals, 10 days
after OA induction (ie, 4 days before treatment discontinuation
on day 14). Rats received either AR786 (MNX+drug; MNX
+drug-discontinued) or vehicle (MNX+vehicle; SHAM
+vehicle).
TrkA-inhibitor selectivity
Assays were carried out on kinase and non-kinase receptors and
channels (see online supplementary text).
Joint pathology
Rats were killed either by an overdose of CO2 (therapeutic
study—day 21) or an overdose of pentobarbital (intraperitoneal)
(preventive study—day 28). Macroscopic chondropathy scoring
was based on the Guingamp classiﬁcation25 (see online supple-
mentary text). Synovium and patellae were removed and frozen
in melting isopentane and tibiofemoral joints were preserved in
neutral buffered formalin, decalciﬁed and processed.26
Histological assessment of cartilage and subchondral bone
including osteophytes was based on the Osteoarthritis Research
Society International recommendations27 (see online supple-
mentary text). Inﬂammation was assessed as joint swelling as
previously described,26 and synovitis grade using H&E-stained
sections according to lining thickness and cellularity22 (see
online supplementary text).
Statistical analysis
Statistical analysis was performed using Prism V.6 (Graph Pad,
San Diego, California, USA). At each time point, data were ana-
lysed using Kruskal–Wallis test followed by post hoc Dunn’s
comparison. Area under the curve (AUC) was also used to
analyse the pain behaviour data over time. Segments analysed
by AUC were determined by treatment changes (eg, before and
after commencement of AR786 administration). Graphs are pre-
sented as mean±SEM (line graphs) or median (scatter grams).
Data in text are presented as mean (95% CI). A two-tailed
p<0.05 was considered signiﬁcant.
RESULTS
Selectivity of AR786
AR786 has a greater selectivity for TrkA over a diverse panel of
kinases, receptors and ion channels (table 1).
OA induction by intra-articular injection of MIA or by MNX
surgery
Intra-articular injection of MIA, or MNX surgery, was each fol-
lowed by increased weight-bearing asymmetry from 3 days after
arthritis induction, compared with non-arthritic saline-injected
or sham-operated controls (ﬁgures 1A, B and 2A). Paw with-
drawal thresholds ipsilateral to the arthritic knee were reduced
by 3 days after arthritis induction in the MIA group and 7 days
in the MNX group compared with non-arthritic controls
(ﬁgures 1C, D and 2B). AUC analysis for both weight-bearing
asymmetry and paw withdrawal thresholds conﬁrmed the pres-
ence of pain behaviour (see online supplementary ﬁgure S1A,C,
E,G). Pain behaviour was sustained in arthritic rats through to
study termination 21 or 28 days after arthritis induction (ﬁgures
1, 2 and see online supplementary ﬁgures S1 and S2).
Intra-articular MIA injection or MNX surgery was each fol-
lowed by structural changes to the joint as indicated by
increased macroscopic chondropathy scores, cartilage matrix
loss, cartilage degeneration score, subchondral bone score and
osteophyte score. Macroscopic chondropathy scores after arth-
ritis induction were signiﬁcantly higher for both vehicle-treated
MIA-injected (day 21) (ﬁgure 3A) and MNX-operated rats (day
21 and 28) (ﬁgure 3B, C) compared with their non-arthritic
controls. MIA-induced OA was characterised by macroscopic
pathology both in medial and lateral tibiofemoral compartments
(ﬁgure 3A, E), whereas chondropathy in MNX-induced OA was
predominantly localised to the medial tibiofemoral joint (ﬁgure
3B, C, H). Cartilage matrix loss, cartilage degeneration scores
and subchondral bone scores were signiﬁcantly higher for the
vehicle-treated MIA-injected rats compared with saline-injected
rats (see online supplementary ﬁgure S3A–C). Cartilage matrix
loss, cartilage degeneration scores and osteophyte scores were
signiﬁcantly higher for the vehicle-treated MNX-operated rats
compared with the sham-operated rats (see online supplemen-
tary ﬁgure S3E, F, H).
Small increases in knee diameter were observed from 3 days
following intra-articular injection of MIA, but did not signiﬁ-
cantly differ from saline-injected rats (ﬁgure 4A). MNX or sham
surgery each resulted in increased knee diameter that persisted
in MNX-operated rats, remaining signiﬁcantly greater than
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sham-operated controls from 14 days after surgery (ﬁgure 4B).
Synovitis scores detected by histological examination were
signiﬁcantly increased after MIA injection (day 21) (ﬁgures 4C
and 5A, B) or MNX surgery (day 28) (ﬁgures 4D and 5D, E)
compared with their non-arthritic controls.
Effects of TrkA inhibitor on established OA pain behaviour
Rats received AR786 for 7 days from 2 weeks after OA induc-
tion (at a time shown previously to correspond to fully estab-
lished OA joint pathology and pain behaviour both in
MIA-induced and MNX-induced models).28 Weight-bearing
asymmetry was reduced following 3 days oral administration of
AR786 in rats with MIA-induced OA (4.3 (−1.9 to 10) %) and
following 5 days treatment in MNX-induced OA (9.2 (5.1 to
13) %)) compared with vehicle-treated arthritic rats at the same
time points (MIA (21 (14 to 29) % p=0.02, ﬁgure 1A) and
MNX (27 (24 to 30) % p=0.02, ﬁgure 1B)). These reductions
in weight-bearing asymmetry following oral administration of
AR786 were conﬁrmed using AUC analysis (see online supple-
mentary ﬁgure S1B,D). Paw withdrawal thresholds were also
increased following 5 days treatment with AR786 in rats with
MIA-induced OA (11 (7 to 15) g) or MNX-induced OA (13 (10
to 15) g)) compared with vehicle-treated arthritic rats (MIA (2.7
(1.2 to 4.2) g p=0.004 ﬁgure 1C) and MNX (6.9 (4.3 to 9.5) g
p=0.01), ﬁgure 1D). Increases in paw withdrawal thresholds
following AR786 administration were conﬁrmed in
MIA-induced OA using AUC analysis, whereas differences in
MNX-induced OA did not reach statistical signiﬁcance (see
online supplementary ﬁgure S1). Both pain behaviours in arth-
ritic rats after treatment with AR786 were comparable with
those in non-arthritic controls, irrespective of the mode of arth-
ritis induction (ﬁgure 1).
Effects of TrkA inhibition on the development of OA pain
behaviour
Rats received AR786 1 day prior to, during and for 28 days
after OA induction by MNX. Treatment with AR786 was with-
drawn in one group of rats (n=10) 2 weeks after arthritis induc-
tion and replaced with vehicle treatment. Weight-bearing
asymmetry was prevented in MNX-operated rats at all time
points when they received AR786 throughout the study (day
28; (4 (−0.1 to 8.1) %) compared with vehicle-treated,
MNX-operated rats (24 (21 to 28) %, p<0.001, ﬁgure 2A)).
Likewise, paw withdrawal thresholds were comparable with
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Figure 1 Effect of therapeutic AR786 on pain behaviour in the MIA and MNX models of OA. MIA injection or MNX surgery each was followed by
an increase in pain behaviour (weight-bearing asymmetry and paw withdrawal threshold) which was sustained until the end of the study (day 21)
(A–D). Administration of AR786 (30 mg/kg twice daily) (treatment) from day 14 completely abolished pain behaviour by day 17 (3 days after start of
treatment) in the MIA-injected rats (A and C). In the MNX-operated rats, pain behaviour was attenuated by day 19 (5 days after start of AR786
treatment) and completely abolished to control levels by day 21 (7 days after start of treatment) (B and D). Data indicate mean±SEM for n=10 rats
per group. Differences between groups were analysed using Kruskal–Wallis test followed by post hoc Dunn’s tests. Signiﬁcance of post hoc tests is
denoted by the number of symbols, for example, *p<0.05; **p<0.01; ***p<0.001. Asterisks (*) denote signiﬁcant differences from vehicle-treated,
saline-injected or sham-operated non-arthritic controls. Hash signs (#) denote signiﬁcant differences from AR786-treated rats with MIA-induced or
MNX-induced OA. MIA, monosodium-iodoacetate; MNX, meniscal transection; OA, osteoarthritis.
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non-arthritic control values in arthritic rats that received AR786
throughout the study (day 28; (12 (9.9 to 14) g) and signiﬁ-
cantly different from values in vehicle-treated MNX-operated
rats (5.8 (4.2 to 7.4) g, p=0.003, ﬁgure 2B). AUC analysis for
both weight-bearing asymmetry and paw withdrawal threshold
showed prevention of pain behaviour with continued AR786
administration (see online supplementary ﬁgure S2A–D).
Withdrawal of AR786 treatment was followed by continuing
reduced weight-bearing asymmetry for 10 days compared with
arthritic rats that had never received the drug (ﬁgure 2A).
Arthritic rats that had their treatment withdrawn did not show a
statistical signiﬁcant difference in weight-bearing asymmetry
compared with arthritic rats that had continued treatment
through to the end of the study (ﬁgure 2A). By contrast, paw
withdrawal thresholds rapidly decreased following withdrawal
of AR786, and 5 days after treatment withdrawal were compar-
able with paw withdrawal thresholds in rats with MNX-induced
OA that never received AR786 (ﬁgure 2B). Paw withdrawal
thresholds in the arthritic rats that had their treatment with-
drawn were signiﬁcantly lower than in arthritic rats with contin-
ued treatment at the end of the study (day 28) (ﬁgure 2B).
Effects of TrkA inhibition on OA joint pathology
We investigated whether observed effects of TrkA inhibition on
pain behaviour might be mediated or moderated by OA joint
pathology.
AR786 had no signiﬁcant effect on joint swelling (ﬁgure 4A, B)
or on macroscopic chondropathy in either OA model, whether
administered in treatment or preventive protocols (ﬁgure 3).
AR786 had no signiﬁcant effect on cartilage surface integrity,
subchondral bone or on osteophyte formation in either OA
model (see online supplementary ﬁgure S3). Administration of
AR786 for 7 days commencing from 14 days after OA induction
by intra-articular injection of MIA was associated with signiﬁ-
cant reductions in synovitis scores compared with vehicle-
treated, MIA-injected rats (ﬁgure 4C). However, no signiﬁcant
reductions in synovitis scores were observed at 4 weeks follow-
ing continuous preventive administration of AR786 in rats with
MNX-induced OA (ﬁgure 4D).
DISCUSSION
We have investigated effects of a novel selective TrkA inhibitor,
AR786 in two rat OA models. OA-associated pain behaviour
was inhibited by AR786 using both preventive and therapeutic
protocols. AR786 also reduced synovitis in one of the models,
whereas we detected no signiﬁcant effect on osteochondral
pathology. Our data suggest potential of a small-molecule, orally
available, selective TrkA inhibitor for the treatment of OA pain.
Intra-articular injection of MIA, or MNX surgery, led to OA
pathology (chondropathy, subchondral bone pathology, osteo-
phytes and mild synovitis) and increased pain behaviours, as
previously reported.26 29 Weight-bearing asymmetry, comparable
with standing pain in people with OA,30 might result from a
combination of nociception and sensitisation.31 Reductions in
hind paw withdrawal thresholds to punctate mechanical stimula-
tion are associated with central sensitisation in rats with OA.21
Central sensitisation might augment joint pain and contribute to
more widespread pain sensitivity in people with OA.31
Sequential progression from peripheral to central nociceptive
mechanisms during the induction of OA in rats is suggested by
early weight-bearing asymmetry followed by reduced paw
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Figure 2 Effect of preventive AR786 treatment on pain behaviour in the MNX model of OA. MNX surgery was carried out on day 0. Either AR786
(30 mg/kg twice daily) (n=20) or vehicle control (5% Gelucire, n=10) was administered orally from 1 day before OA induction (day −1, treatment).
AR786 treatment was either continued (n=10), or discontinued and replaced with vehicle treatment (n=10), 14 days after OA induction (treatment
±). MNX surgery was followed in vehicle-treated control rats by increases in pain behaviour (A; weight-bearing asymmetry and B; paw withdrawal
threshold) which were maintained until the end of the study (day 28). The development of pain behaviour was completely prevented during the
period of AR786 administration. By day 24, 10 days after discontinuation of AR786 treatment in MNX-operated rats, weight-bearing asymmetry was
signiﬁcantly greater than in sham-operated rats, but did not reach the levels observed in MNX-operated, vehicle-treated rats and did not differ
signiﬁcantly from rats that continued to receive AR786 through to the end of the study (day 28) (A). Paw withdrawal thresholds were reduced at day
19, 5 days after treatment discontinuation in MNX-operated rats that had received AR786 treatment until day 14. By this time, paw withdrawal
thresholds in MNX-operated rats did not differ signiﬁcantly between those in which AR786 had been discontinued compared with those that had
never received AR786 (MNX-operated, vehicle-treated rats). Paw withdrawal thresholds 7 days after treatment discontinuation in MNX-operated rats
were signiﬁcantly reduced compared with sham-operated, vehicle-treated rats and 14 days after treatment discontinuation paw withdrawal
thresholds were reduced compared with MNX-operated rats that continued to receive AR786 (B). Data are mean±SEM of n=10 rats per group.
Differences between groups were analysed using Kruskal–Wallis test followed by post hoc Dunn’s tests. Signiﬁcance of post hoc tests is denoted by
the number of symbols, for example, *p<0.05; **p<0.01; ***p<0.001. Asterisks (*) denote differences from sham-operated, vehicle-treated control
rats. Hash signs (#) denote differences from MNX-operated rats that continued to receive AR786. Dollar signs ($) denote differences in
MNX-operated rats after AR786 discontinuation compared with MNX-operated rats that had received vehicle treatment throughout the experiment.
Per cent sign (%) denotes differences from MNX-operated rats after AR786 discontinuation compared with MNX-operated rats that continued AR786
treatment. MNX, meniscal transection; OA, osteoarthritis.
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withdrawal thresholds, and is further indicated by electrophysio-
logical, cellular and molecular studies in rat OA models.32 33
Minor differences in pain phenotypes reported between MIA
and MNX OA models might reﬂect heterogeneity also observed
between different people with OA. Reduced paw withdrawal
thresholds in MIA-induced OA were more pronounced than in
MNX-induced OA, as previously reported,28 consistent with a
greater contribution from central pain processing.34 35
Consistent analgesic effects of TrkA inhibitors between models
suggest that our ﬁndings might be relevant to OA in general,
rather than being speciﬁc to the mode of OA induction.
However, caution must be exercised before generalising from
laboratory ﬁndings to human OA. Rat models develop rapidly
and pain mechanisms might differ in early compared with long
established OA. Although rat OA models display similar histo-
logical and pain behavioural characteristics to those observed in
chronic human OA,29 preclinical studies can only guide, rather
than accurately predict, results of research in humans.
Oral AR786 administration abolished pain behaviour in both
MIA and MNX models in both preventive and therapeutic
studies. Our ﬁndings extend previous reports of analgesic effects
of Trk inhibitors in non-malignant skeletal and bone cancer
pain17 24 and indicate that analgesic effects of Trk inhibition
might be mediated speciﬁcally by TrkA. NGF blockade using a
TrkA–IgG fusion protein also reduced pain behaviour in rodent
OA.9 Our ﬁndings indicate a role also for the high-afﬁnity NGF
receptor, TrkA, and demonstrate the potential for a small-
molecule selective inhibitor of TrkA as a novel therapeutic strat-
egy in OA.
AR786 displays low central nervous system penetration, with
plasma:CSF (cerebrospinal ﬂuid) ratios approximately 10:1.36
However, TrkA inhibition attenuated reduced paw withdrawal
Table 1 Trk selective inhibitor AR786 is >1000 fold selective for TrkA over a diverse panel of kinases, receptors, channels and transporters
Kinases CNS receptors Nociceptive receptors
AKT1 Flt3 MAPKAP-K2 PKCα SGK2 Adenosine A2A Bradykinin B2
AKT2 Flt4 MAPKAP-K3 PKCβI SGK3 Adenosine A3 Cannabinoid
AKT3 Fms MAPKAP-K5 PKCβII SIK Adrenergic α1 CGRP1
ALK Fyn MARK1 PKCδ SRC Adrenergic α2 Opiate δ
ALK4 GRK5 MARK2 PKCε SRPK1 Adrenergic β Opiate κ
AMPK GRK6 MEK1 PKCη SRPK2 Androgen Opiate m
ARK5 GRK7 MELK PKCγ STK33 Dopamine D1 Phorbolester
AURKA GSK3α MKK7β PKCι Syk Dopamine D3 Purinergic
Abl-P GSK3β MKNK2 PKCθ TAK1 GABAA (flunitrazepam) Tachykinin NK1
Abl2 HIPK1 MLK1 PKCζ TAO1 GABAA (Muscimol) Sigma
Ax1 HIPK2 MRCKα PKD1 TAO2 GABAB Inflammatory response
BLK_m HIPK3 MRCKβ PKD2 TAO3 Glutamate 1EP4
BTK Haspin MSK1 PRK2 TBK1 GPR103 Glucocorticoid
Bmx Hck MSK2 PRKG1α TLK2 Imidazoline 12 Histamine H1
BrSK1 IGF-1R MSSK1 PRKG1β TNK2 Melatonin MT2 Histamine H2
BrSK2 IKKα MST1 PTK5 TSSK1 Muscarinic (non-selective central) Histamine H4
CAMK1 IKKβ MST2 PTK6 TSSK2 Muscarinic oxotremorine Leukotriene
CAMK1d IR MST3 PhKγ2 Tie2 Neuropeptide Y1 PAF
CAMK2b IR Act MYLK Pim-1 Txk Neurotensin CNS transporters
CAMK2g IRAK1 Mer Pim-2 ULK2 Nicotine Acetylcholine GABA
CAMK4 IRAK4 Met Pim-3 ULK3 Nicotine Acetylcholine α1 Norepinephrine (NET)
CDK1/cyclinB IRR MuSK Plk1 VRK2 Rolipram Serotonin (SERT)
CDK2/cyclinA ITK NEK11 Plk2 WNK2 Serotonin 5-HT1A Channels
CDK2/cyclinE JAK2 NEK2 Plk3 WNK3 Serotonin 5-HT2B Calcium Channel l-Type
CDK3/cyclinE JAK3 NEK3 PrKX Yes Serotonin 5-HT3 Calcium Channel N-type
CDK5/p25 JNK1α1 NEK6 RIPK2 ZAP-70 Somatostatin sst5 Miscellaneous
CDK5/p35 JNK2α2 NEK7 ROCK-I c-Raf Thyroid Hormone Endothelin
CDK6/cyclinD3 JNK3 NLK ROCK-II eEF-2K EGF
CDK7/cyclinH/MAT1 KDR PAK2 Ret mTOR VIP1
CDK9/cyclinT1 KIT PAK3 Ron mTOR/FKBP12
CHK1 LIMK1 PAK5 Ros p38α
CHK2 LKB1 PAK6 Rse p38β
CK1_v 1OK PASK Rsk1 p38δ
CK1δ Lck PDGFRα Rsk2 p38γ
CK1γ1 Lyn PDGFRβ Rsk3 p790S6K
CK1γ2 MAP3K5 PDK1 Rsk4
CK1γ3 MAP4K2 PKACα SGK
The TrkA selective inhibitor AR786 demonstrated sub-nanomolar cellular inhibition of TrkA (IC50=0.6 nM) and >1000 fold selectivity over TrkB (IC50=1147 nM), and TrkC
(IC50=1834 nM). AR786 exhibited a high level of selectivity over a panel of kinases run at the ATP Km at 1.0 and 10 nM compound concentrations respectively as well as a panel of
non-kinase receptors and ion channels run at a 10 nM compound concentration. CNS, central nervous system; TrkA, tropomyosin receptor kinase A.
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thresholds, a behavioural correlate of central sensitisation. NGF
might induce central sensitisation indirectly by increasing BDNF
release from primary afferent neurons.37 38 Furthermore, syno-
vitis might drive central sensitisation during arthritis.26
Increased paw withdrawal thresholds relapsed more quickly
after treatment withdrawal than did weight-bearing asymmetry,
suggesting that TrkA inhibition has a more sustained effect on
peripheral pain processing than on central sensitisation. It is
likely that increases in paw withdrawal thresholds following
TrkA inhibition result from blocking peripheral actions of NGF,
although further research would be required to determine
whether low concentrations of AR786 in the CSF could alter
central pain processing.
We demonstrate that rats with OA that received 14 days pre-
emptive treatment continued to display improved weight-
bearing asymmetry for at least 10 days after treatment
withdrawal, despite displaying macroscopic evidence of OA
pathology. This raises the potential that TrkA inhibition might
prevent the transition to a sensitised state if administered for
short periods during critical phases of OA development. This
contrasts, for example, with drugs such as indomethacin,
which, while reducing weight-bearing asymmetry in
MNX-induced OA, require continued treatment for mainten-
ance of effect, with a relapse of weight-bearing asymmetry to
levels that are comparable with those seen in arthritic rats that
have never received indomethacin only 3 days after treatment
withdrawal.26 32
Synovitis is associated with pain in human OA.2 Inﬂammation
generates factors that activate or sensitise joint nociceptors,
including NGF.39 TrkA activation increases inﬂammatory and
sensitising neuropeptide release from sensory nerves, including
substance P and calcitonin gene-related peptide.40–42
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Figure 3 Macroscopic appearances of chondropathy in the MIA and MNX models of OA. Both OA models displayed macroscopic evidence of
chondropathy (A–C), 21 days (A and B) or 28 days (C) after arthritis induction. Administration of AR786 had no signiﬁcant effect on macroscopic
evidence of chondropathy in either treatment (A and B) or preventive (C) protocols. Tibial plateaux from 21 days after saline injection (D) or sham
operation (G) show normal appearances with no evidence of cartilage erosion. Tibial plateaux from rats 21 days after MIA injection (E and F) or
MNX surgery (H and I), and following 7 days treatment with Gelucire vehicle (E and H) or AR786 (F and I) display erosions of the articular cartilage
in the weight-bearing areas (black arrows), some of which extend to the underlying subchondral bone. Osteophytosis (red arrows) is also apparent
in the medial tibial plateaux of the MNX-operated rats (H and I). Appearances are similar in knees from vehicle-treated and AR786-treated rats.
Scoring (A–C) was done using a dissecting microscope at 10 times magniﬁcation. Scatter plots show medians of n=10 rats/group. Signiﬁcance of
post hoc tests is denoted by the number of symbols, for example, *p<0.05; **p<0.01; ***p<0.001. Asterisks (*) denote differences from
vehicle-treated, saline-injected or sham-operated controls. In (C), MNX-operated, AR786-treated rats either continued to receive AR786 until the end
of the experiment (AR786+), or AR786 treatment was discontinued and replaced by vehicle treatment from day 14 until the end of the experiment
(AR786−). Photomicrographs (D–I) show medial and lateral tibial plateaux from a rat with the median chondropathy score from each group. MIA,
monosodium-iodoacetate; MNX, meniscal transection; OA, osteoarthritis.
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Furthermore, TrkA might be expressed by mast cells,43 synovial
ﬁbroblasts44 and macrophages45 and inﬂammatory cell activa-
tion by NGF leads to the upregulation and release of inﬂamma-
tory mediators, which might further activate or sensitise joint
nociceptors.46 47 AR786 reduced synovitis in rats with
MIA-induced OA, but did not signiﬁcantly reduce either knee
swelling or synovitis in rats with MNX-induced OA. These
apparent differences might reﬂect different mechanisms or
severity28 of inﬂammation between the two models. Further
research would be required to determine the mechanisms under-
lying the anti-inﬂammatory effects of AR786, and whether
human OA displays AR786-sensitive inﬂammation.
Chondropathy is a hallmark of human OA,48 and cartilage
changes are associated with pain severity.49 Clinical trials of
NGF-blocking antibodies were put on hold due to the rare
occurrence of RPOA.50 Small reductions in macroscopic and
microscopic chondropathy scores observed following treatment
with AR786 did not reach statistical signiﬁcance and are unlikely
to have made any major contribution to the observed reductions
in pain behaviour. However, more sustained synovitis inhibition
might facilitate pain relief in OA in part by reducing joint
damage.51 Our studies were not powered to detect rare adverse
effects on joint structure.
In conclusion, the inhibition of NGF activity by blocking
TrkA reduced pain behaviour in two rat models of OA.
Reductions in pain behaviour were observed both using prevent-
ive and treatment protocols, and were sustained for up to
10 days despite treatment discontinuation. Clinical trials of
NGF blockade have demonstrated potential of blocking the
NGF/TrkA pathway for the relief of OA pain. Further research
should address possible differences between NGF-blockade and
selective TrkA inhibition, and the potential for sustained beneﬁt
from discontinuous treatment, in order to help realise the
potential of NGF pathway inhibition for OA pain relief.
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Figure 4 Effect of AR786 on MIA-induced or MNX-induced knee inﬂammation. Small changes in knee diameter were observed after intra-articular
injection of MIA or saline (A), or after MNX surgery or sham surgery (B), as indicated by small differences between injected/operated and
contralateral knees. Either AR786 (30 mg/kg twice daily) or vehicle (5% Gelucire) control was administered orally from day 14 (treatment). Knee
diameters did not differ signiﬁcantly between MIA-injected or saline-injected knees, nor between MIA-injected rats treated with either AR786 or
vehicle (A). Knee diameter differences between operated and contralateral, non-operated knees were greater in MNX-operated than in
sham-operated rats from 14 days after surgery (B). Differences in knee diameter between AR786-treated and vehicle-treated, MNX-operated rats at
day 21 (7 days after the start of treatment) did not reach statistical signiﬁcance. Synovitis scores, determined by histology, were signiﬁcantly higher
for MIA-injected rats (C) at 21 days and MNX-operated rats (D) at 28 days compared with saline-injected or sham-operated controls. Synovitis scores
were reduced in MIA-injected rats following treatment for 7 days with oral AR786 compared with Gelucire vehicle-treated controls (C). Synovitis
scores were not inhibited by preventive administration of AR786 in MNX-operated rats (D). Data are median of n=10 rats/group (A and B).
Signiﬁcance of post hoc tests is denoted by the number of symbols, for example, *p<0.05; **p<0.01; ***p<0.001. Asterisks (*) denote differences
from saline-injected or sham-operated, vehicle-treated control rats. Hash sign (#) denotes differences from MIA-injected rats that received AR786. In
(D), MNX-operated, AR786-treated rats either continued to receive AR786 until the end of the experiment at day 28 (AR786+), or AR786 treatment
was discontinued and replaced by vehicle treatment from day 14 (AR786−). No signiﬁcant differences were observed between continued and
discontinued treatment groups. MIA, monosodium-iodoacetate; MNX, meniscal transection.
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